Onychomysosis
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He matikuku i pangia e Onychomysosis
Ko te waewae o te tangata kua pangia e te whao harore mo te tekau wiki ki roto i te akoranga rongoa a-waha terbinafine. Tuhia te roopu o te tipu o nga whao hauora i muri i nga toenga o nga whao kua pangia.
References
Ko nga antifungal punaha te maimoatanga tino whai hua. Ko nga tātari-meta e whakaatu ana i nga reiti whakaora mate mycotic e whai ake nei: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Ko te whakaheke i nga whao ka piki ake nga reeti rongoa. He iti ake te whai hua o te rongoa o runga me te ciclopirox ; he reiti rahunga neke atu i te 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Ko te Onychomycosis he mate harore e pa ana ki nga whao. Na te dermatophytes te take, ka kiia ko te tinea unguium. Kei roto i te Onychomycosis nga mate na te dermatophytes, te rewena, me te koriri. Ko te raruraru maikuku ehara i te mate harore ka kiia ko te nail dystrophy. Ahakoa ka pa ki nga maikuku me nga matikuku, he nui ake te onychomycosis maikuku. Ka matapakihia e tenei tuhinga nga momo ahuatanga o te onychomycosis maikuku, penei i tona paanga, nga momo haumanu, nga waahanga, te taatai, me te maimoatanga. Ahakoa ehara i te mea whakamate, ka taea e te onychomycosis te arahi ki nga raru nui penei i te cellulitis, sepsis, te mate wheua, te kino o te kiko, me te mate maikuku.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Ko te Terbinafine he rongoa hei patu i nga mate harore ma te aukati i te squalene epoxidase. He whai hua ki te maha o nga momo harore kiri, ka whakaaetia mo te rongoa i te harore maikuku ina tangohia ma te waha. Ahakoa ko te nuinga o nga paanga o te taha penei i te mahunga me nga take o te puku he iti noa iho ka haere noa atu, ka rereke nga huringa o te reka (dysgeusia) mai i te ngawari ki te kino, i etahi wa ka heke te taumaha. He onge noa nga huringa reka tonu engari kua korerotia.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Ko te Onychomycosis he mate harore e pa ana ki nga whao. Tata ki te 90% o nga mate maikuku me te 75% o nga mate maikuku na te harore (Trichophyton mentagrophytes, Trichophyton rubrum) . Ko nga tohu ko te paheketanga o nga whao, te matotoru, te wehe mai i te moenga o te whao, me te tipu nui. Ko te nuinga o nga maimoatanga ko nga rongoa-waha penei i te terbinafine, itraconazole ranei, me nga maimoatanga o runga hei whiringa mo nga keehi ngawari me te ngawari.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Ko te rongoa antifungal terbinafine i tangohia e te mangai ko te ahua tino whai hua engari ko te terbinafine e pa ana ki te taha o te ate.
Ka puta te onychomysosis i roto i te 10 paihēneti o te taupori pakeke, he nui ake te pa o te hunga pakeke. He maha ake nga wa ka pa ki nga tane i nga wahine. Ko te onychomysosis te tohu mo te haurua o te mate whao. Ko te tikanga ko te ahua kino o nga matikuku ka puta mai i nga take ke atu i te onychomycosis.
○ Maimoatanga - Rongoa OTC
He uaua ki te rongoa i te onychomycosis me nga rongoa rongoa na te mea he uaua mo nga raau taero ki te kuhu ki nga maikuku kua matotoru.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Maimoatanga
Ko te maimoatanga mo te wa roa ka hiahiatia kia tangohia ra ano te maikuku kua pangia.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer